Investigational drug · Phase 2
EDIT-401
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Heterozygous Familial Hypercholesterolemia (HeFH).
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "EDIT-401"
First trial start
2026
Nov 2026
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "EDIT-401", any sponsor or status.
Conditions studied
As listed on its trial records.
- Heterozygous Familial Hypercholesterolemia (HeFH)
Approved drugs for the same conditions: High cholesterol · Cardiovascular and metabolic
Largest trials
Live from ClinicalTrials.gov: studies naming "EDIT-401" as an intervention, largest first.
- EDIT-401 in Adults Who Require Additional Lowering of Low-Density Lipoprotein Cholesterol (LDL-C)Not yet recruiting
Editas Medicine, Inc.Industry
NCT07894887 · 56 participants (planned) · Start Nov 2026 · Primary completion Jun 2029
Drug: Drug: EDIT-401 · For: Heterozygous Familial Hypercholesterolemia (HeFH)
Sites: Charlestown, Australia; Perth, Australia
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Heterozygous Familial Hypercholesterolemia (HeFH)
- QLC7401Phase 34 trials
Qilu Pharmaceutical Co., Ltd. · Primary Hypercholesterolemia or Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH)
- SYH2053Phase 34 trials
CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. · Non-familial Hypercholesterolemia and Mixed Hyperlipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), Hypercholesterolemia and Mixed Hyperlipidemia
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.